SEC Form 10-K filed by Elanco Animal Health Incorporated
$ELAN
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2024 | $18.00 | Buy | UBS |
| 12/2/2024 | $14.00 | Market Perform | Leerink Partners |
| 9/19/2024 | $17.00 → $15.00 | Overweight → Equal-Weight | Morgan Stanley |
| 1/5/2024 | $13.00 → $20.00 | Hold → Buy | Stifel |
| 12/19/2023 | $17.00 | Buy | Jefferies |
| 12/15/2023 | $16.00 | Equal-Weight → Overweight | Morgan Stanley |
| 12/7/2023 | $18.00 | Outperform | Exane BNP Paribas |
| 4/20/2023 | $14.00 | Equal Weight → Overweight | Barclays |
SD - Elanco Animal Health Inc (0001739104) (Filer)
8-K - Elanco Animal Health Inc (0001739104) (Filer)
10-Q - Elanco Animal Health Inc (0001739104) (Filer)
GREENFIELD, Ind., May 28, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Robert VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025. VanHimbergen's appointment follows an extensive and competitive search as part of the company's commitment to long-term, sustained value creation. VanHimbergen succeeds Todd Young, who will remain with the company as an advisor through August 31, 2025, to facilitate a smooth transition. VanHimbergen currently serves as the Senior Vice President and Chi
Ma brings deep manufacturing and innovation expertise GREENFIELD, Ind., Nov. 12, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma brings extensive global leadership experience in biopharmaceutical development and manufacturing, further strengthening Elanco's expertise in these critical areas. "We are delighted to add Stacey to the Elanco Board," said Lawrence Kurzius, Chairman of the Elanco Board of Directors. "Her deep understanding of product developmen
New Directors Join the Board's Renamed Finance, Strategy and Oversight Committee Reaches Cooperation Agreement with Ancora GREENFIELD, Ind., April 1, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors (the "Board"), effective immediately, expanding the Board to 14 members. Ms. Turner brings significant global experience in both the animal health and broader healthcare industries. She has held senior leadership positions at IDEXX Labora
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
UBS initiated coverage of Elanco Animal Health with a rating of Buy and set a new price target of $18.00
Leerink Partners initiated coverage of Elanco Animal Health with a rating of Market Perform and set a new price target of $14.00
Morgan Stanley downgraded Elanco Animal Health from Overweight to Equal-Weight and set a new price target of $15.00 from $17.00 previously
GREENFIELD, Ind., May 28, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Robert VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025. VanHimbergen's appointment follows an extensive and competitive search as part of the company's commitment to long-term, sustained value creation. VanHimbergen succeeds Todd Young, who will remain with the company as an advisor through August 31, 2025, to facilitate a smooth transition. VanHimbergen currently serves as the Senior Vice President and Chi
GREENFIELD, Ind., May 16, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced that management will participate in upcoming investor conferences. On Thursday, May 22, Jeff Simmons, president and CEO, will participate in the BNP Paribas 2nd Annual Animal Health Day at 12:00 p.m. ET. On Thursday, May 29, Jeff Simmons, president and CEO, and Todd Young, executive vice president and CFO, will participate in a fireside chat at Stifel 2025 Jaws & Paws Conference at 8:00 a.m. ET. Live audio webcasts will be available in the "Events and Presentations" sec
Accelerating Debt Paydown in 2025 First Quarter 2025 Financial Results:Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic constant currency growthReported Net Income of $67 million, Adjusted Net Income of $184 millionAdjusted EBITDA of $276 million, or 23.1% of RevenueReported EPS of $0.13, Adjusted EPS of $0.37Net leverage ratio of 4.4x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,510 to $4,580 million, with $65 to $70 million increase since February driven by foreign exchange tailwind; continue to expect accelerating organic constant currency revenue growth to mid-single digitsRaising 2025 innovation revenue target to $660 to $740 millionReported
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
Accelerating Debt Paydown in 2025 First Quarter 2025 Financial Results:Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic constant currency growthReported Net Income of $67 million, Adjusted Net Income of $184 millionAdjusted EBITDA of $276 million, or 23.1% of RevenueReported EPS of $0.13, Adjusted EPS of $0.37Net leverage ratio of 4.4x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,510 to $4,580 million, with $65 to $70 million increase since February driven by foreign exchange tailwind; continue to expect accelerating organic constant currency revenue growth to mid-single digitsRaising 2025 innovation revenue target to $660 to $740 millionReported
GREENFIELD, Ind., April 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its first quarter 2025 financial results on Wednesday, May 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/defau
GREENFIELD, Ind., Feb. 4, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-pr